Amicus Therapeutics (NASDAQ: FOLD) is a patient-focused worldwide biotech corporation that focuses on delivering, developing, and discovering novel medication products for rare diseases. The company recently announced that it was granted approval by the European Commission for Galafold, which is designed for use in patients aged 12 to 16 years who weigh about 45 kgs. These patients need to be suffering from Fabry disease and should have amenable mutations. The Galafold treatment has already been approved in many different locations all across the globe. This includes Japan, Europe, and the US, for patients who’ve got an amenable mutation or variant.
Senior Management
Amicus Therapeutics’ Chief Operating Officer and President, Bradley Campbell, claimed that this approval represented a transformative time for the European Union’s Fabry community. Why? Because now those individuals as young as twelve years who’ve got amenable variants have a potential treatment, which will be the first one in over fifteen years. The COO said that the company was grateful to being a part of this passionate community, more so the families, physicians and, of course, the patients themselves who’ve helped make this study possible via their participation in the trials. He also recognized the dedicated Amicus team and regulators behind the study. He claimed that this achievement demonstrated Amicus’ mission to concentrate on changing the lives of patients battling rare diseases.
Lysosomal Storage Disease Unit’s Managing Director, Una Ramaswami, said that the expanded approval proved to be a significant step forward for folks that battle or are affected by Fabry complications. She said that they’d continue to try and boost awareness of the different rare diseases that attack young people. In addition, she claimed that this approval now ensured that patients, both adult and pediatric, have access to a convenient oral therapy option.
The amendment in this agreement was supported by a one-month interim pharmacokinetics and safety information derived from the AT1001-020 Study, which was a two-stage, multicenter, open-label clinical study.
